Antonio Bernardo

Primario

Palumbo R, Sottotetti F, Bernardo A. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? Ther Adv Med Oncol 8(3):209-29, 2016.

Del Re M, Quaquarini E, Sottotetti F, Michelucci A, Palumbo R, Simi P, Danesi R, Bernardo A. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. Pharmacogenomics 17(1):5-9, 2016.

Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. Oncologist 20(8):880-9, 2015.

Palumbo R, Sottotetti F, Trifirò G, Piazza E, Ferzi A, Gambaro A, Spinapolice EG, Pozzi E, Tagliaferri B, Teragni C, Bernardo A. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther 9:2189-99, 2015.

Palumbo R., Sottotetti F., Riccardi A., Teragni C., Pozzi E., Quaquarini E., Tagliaferri B., Bernardo A.

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol 5(6): 334–350, 2013

Silvestris N., Pantano F, Ibrahim T., Gamucci T., De Vita F., Di Palma T., Pedrazzoli P., Barni S., Bernardo A., Febbraro A., Satolli M.A., Bertocchi P., Catalano V., Giommoni E., Comandone A., Maiello E., Riccardi F., Ferrara R., Trogu A., Berardi A., Leo S., Bertolini A., Angelini F., Cinieri S., Russo A., Pisconti S., Brunetti A.E., Azzariti A., Santini D. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey”. PLoS One 8(10): e74402, 2013

Cameron D., Brown J., Dent R., Jackisch C., Mackey J., Pivot X., Bernardo A., Steger G.G,. et al.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase III trial”. Lancet Oncol 14(10):933-42, 2013

Fuccio C., Palumbo R., Frascaroli M., Spinapolice E., Castellucci P., Ceci E., Latella E., D'Ambrosio D., Bernardo A., Trifirò G. Comparison between F-18-fluoride PET/CT and Tc-99m-MDP bone scintigraphy in the detection of bone metastases from clear cell renal carcinoma (RCC): a prospective pilot study”. Eur J Nucl Med Mol I 40(2): S468-S469, 2013

Strada M.R., Palumbo R., Bernardo A., Riccardi A., Teragni C., Poggi G., Frascaroli M., Amatu A., Montagna B., Sottotetti F., Tagliaferri B., Bernardo G. Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials”. Clin Breast Cancer 12(1): 30-9, 2012

Poggi G., Riccardi A., Quaretti P., Teragni C., Delmonte A., Amatu A.,    Saini G., Mazzucco M., Bernardo A., Palumbo R., Canto A., Bernieri S., Bernardo G. Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver”. Anticancer Res 27: 2911-16, 2007